Medalogix, the leading data science and clinical decision support company specializing in the advancement of patient care in home health, hospice, and strategic payor initiatives in the home, and Amedisys, a leading provider of home health, hospice and high-acuity care in the home, announced an expanded partnership with the implementation of Medalogix Pulse for Home Health patients.
“We continue to ask our teams to manage changes in patient acuity, payer mix, and regulatory challenges, all while being faced with continued staffing challenges,” said Cyndi Shook, SVP Clinical Operations at Amedisys. “When Medalogix showed us Pulse, we knew we had found an incredible tool for empowering our clinicians with essentially real-time clinical insights that can help improve patient outcomes and staff satisfaction.”
“Pulse is a game changer in how we manage patients,” said Shook. “Our Clinical Managers are looking at Pulse first thing every day as it provides a current snapshot of clinical status of each patient, saving staff time, and based on this we can deploy capacity to the right patients at the right time.” Amedisys manages an ADC of over 78,000 patients in Pulse across 354 branch locations.
Also Read: Cynerio Strengthens Its Partner Ecosystem in North America to Combat Rising Healthcare Cyber Threats
Amedisys is leveraging Pulse clinical decision support at every stage of a home health patient’s journey. Over 91% of patients are receiving visit recommendations at the start of care, helping to maintain industry leading visits-per-episode. Then, visit-by-visit, Pulse is stratifying patients’ likelihood of hospitalization, empowering effective and efficient use of clinical resources and appropriate, timely changes to care plans as patients’ needs change, minimizing the potential of rehospitalizations/transfer to inpatient facilities (TIF). Towards the end of episode, Amedisys clinical team is retrieving end of episode recommendations that support individualized care plan updates, including helping to inform recertification versus discharge decisions which drive best in class patient outcome. At any time during the episode, providers can see and plan actions in Pulse to improve LUPAs due to unplanned gaps in care, HHVBP measures, and more.
“As the industry continues to see evolving headwinds, there is one constant, and that is quality of care,” said Elliott Wood, CEO of Medalogix. “Our mission has always been to provide individualized patient care, and by creating more visibility to the dynamic changes in condition, visit by visit, of patients in Pulse, providers can now manage patients to drive outcomes regardless of complexities the industry may be facing.”
“Pulse has been an effective approach in our strategy to manage Medicare Advantage patients,” added Nick Muscato, Chief Strategy Officer, Amedisys. “Medalogix is a primary enabler for how Amedisys can take risk with payers and shift to case rate structure. Pulse is helping us manage episodes more effectively; by managing towards individual patient needs we are seeing an average CMS Compare STAR rating of 4.4, compared to the industry average of 3.25. This empowers us to enter Medicare Advantage negotiations a little differently than our competitors.”
SOURCE: PRNewswire